Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,963,561 shares of the company’s stock after selling 10,545 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.17% of Teva Pharmaceutical Industries worth $35,383,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. WCM Investment Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $1,051,000. Venturi Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter worth $60,000. State of New Jersey Common Pension Fund D lifted its stake in shares of Teva Pharmaceutical Industries by 3.7% during the third quarter. State of New Jersey Common Pension Fund D now owns 473,509 shares of the company’s stock worth $8,533,000 after buying an additional 16,700 shares during the period. Atria Investments Inc grew its holdings in shares of Teva Pharmaceutical Industries by 135.4% during the third quarter. Atria Investments Inc now owns 30,856 shares of the company’s stock valued at $556,000 after buying an additional 17,746 shares during the last quarter. Finally, Greenwood Capital Associates LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $4,267,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 1.9 %

Shares of Teva Pharmaceutical Industries stock opened at $16.43 on Friday. The company has a fifty day simple moving average of $17.78 and a 200-day simple moving average of $17.22. Teva Pharmaceutical Industries Limited has a 12-month low of $8.64 and a 12-month high of $19.31. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The stock has a market cap of $18.61 billion, a price-to-earnings ratio of -19.33, a PEG ratio of 1.32 and a beta of 0.87.

Wall Street Analyst Weigh In

Several research firms have weighed in on TEVA. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Barclays upped their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $19.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.